AI and Metabolomics: Revolutionizing Early Alzheimer's Detection

As Taiwan officially entered a super-aged society in 2025, the prevalence of dementia has emerged as a critical public health challenge. With the dementia population expected to exceed 600,000 by 2050, the pressure on individual health, family care, and national long-term care systems is intensifying.

Breaking the Barrier of Late Diagnosis

Traditional diagnostic methods for Alzheimer’s Disease often rely on cognitive screening questionnaires, such as the MMSE, or imaging techniques like MRI. However, these tools typically identify the disease only after significant clinical symptoms, such as memory loss and disorientation, have appeared.

By the time brain atrophy is visible on an MRI, irreversible neuronal damage may have been progressing silently for 10 to 20 years. This lag often results in patients missing the optimal window for early intervention.

While more precise early diagnoses exist, they often involve invasive lumbar punctures to collect cerebrospinal fluid or prohibitively expensive PET scans. These barriers make early screening inaccessible for many in primary care and preventive medicine settings.

Did You Know? Among the population aged 90 and older in Taiwan, the prevalence of dementia reaches 36.88%, meaning approximately one in every three individuals in this age group is affected.

The Science of Metabolomics and AI

To address these limitations, the startup Homnia has introduced metabolomics technology and AI models developed by the translational medicine team at the Stanford University School of Medicine. This approach utilizes routine blood tests to detect metabolic abnormalities 8 to 10 years earlier than traditional clinical indicators.

Using high-sensitivity medical-grade mass spectrometry (LC-MS/MS), clinicians can quantify over 2,000 metabolite molecules from a single blood sample. These metabolites reflect the real-time interaction between genetic expression, environment, and lifestyle.

A key breakthrough is the identification of myo-inositol, a biomarker that increases in the blood of high-risk groups 10 to 20 years before the onset of mild cognitive impairment or clinical symptoms. This non-invasive method could potentially replace the need for painful spinal punctures.

Global Validation and Personalized Care

The efficacy of blood metabolite biomarkers is supported by a large-scale study published in Nature Communications in November 2024. analysing biobanks from the UK, Estonia, and Finland with over 700,000 participants, the research confirmed that these markers could predict nine major chronic diseases, including Alzheimer’s, 8 to 10 years earlier than traditional risk factors.

The study further indicated that metabolite scores may offer predictive capabilities that exceed those of Polygenic Risk Scores (PRS) for most diseases.

Expert Insight: Samantha Carter notes that shifting the diagnostic window from the symptomatic stage to a pre-symptomatic stage transforms the medical narrative. By identifying metabolic shifts decades before cognitive decline, the focus moves from managing an inevitable decline to actively attempting to reverse the disease’s trajectory.

Capturing the Golden Window for Intervention

Dr. Chia-Ju Tsai, CEO of Homnia and Assistant Professor at the National Taiwan University College of Medicine, emphasizes that early risk detection is not a “death sentence” but an opportunity for reversal. Detecting myo-inositol abnormalities allows medical teams to utilize a golden window of intervention to curb the progression of the disease.

Artificial intelligence could be key for early detection of Alzheimer's

Metabolomics allows for personalized precision medicine rather than generic advice. For instance, those with specific inflammatory or lipid metabolism abnormalities may be advised to supplement with Omega-3 fatty acids (DHA).

Similarly, if a patient’s risk is elevated due to high homocysteine levels, practitioners may recommend active B-complex vitamins, such as vitamin B12 and active folate. This data-driven approach allows the effectiveness of “brain-protecting” investments to be objectively quantified.

The Future of Brain Health Management

The transition toward non-invasive metabolic assessments may likely reduce the burden on healthcare systems by moving away from a passive “wait-and-see” model. This shift could potentially empower individuals to take control of their brain health through quantified, personalized prevention.

As these technologies integrate further into preventive medicine, the standard of care will evolve to include routine metabolic screening as a primary defence against neurodegeneration.

Frequently Asked Questions

How much earlier can metabolomics detect Alzheimer’s compared to traditional methods?
Metabolite biomarkers can predict the occurrence of the disease 8 to 10 years earlier than traditional clinical risk factors, while specific markers like myo-inositol can be detected 10 to 20 years before clinical symptoms appear.

What is the primary advantage of this new test over existing diagnostics?
Unlike invasive lumbar punctures or expensive PET scans, this method uses a routine, non-invasive blood test to provide an objective early warning of brain health.

Can early detection actually change the outcome of the disease?
According to Dr. Chia-Ju Tsai, early detection provides a “golden intervention window” that allows for personalized adjustments—such as specific nutritional supplements based on metabolic offsets—to help curb or reverse the disease’s progression.

Do you believe that routine blood screening for neurological risks should become a standard part of healthcare for older adults?

AI and Metabolomics: Revolutionizing Early Alzheimer’s Detection